Background Despite standard curative-intent treatment with neoadjuvant cisplatin-based
chemotherapy, followed by radical surgery in eligible patients, muscle-invasive urothelial …

Testicular cancer is relatively uncommon and accounts for <1% of all male tumors. However,
it is the most common solid tumor in men between the ages of 20 and 34 years, and the …

Urothelial carcinoma is a common malignancy that carries a poor prognosis when the disease
includes muscle invasion. Metastatic urothelial carcinoma is almost uniformly fatal. The …

PURPOSE Platinum-based chemotherapy for first-line treatment of metastatic urothelial
cancer is typically administered for a fixed duration followed by observation until progression.“…

Purpose This study sought to define and identify drivers of trends in cost and use of targeted
therapeutics among privately insured nonelderly patients with cancer receiving …

PURPOSE Patients with locally advanced or metastatic urothelial cancer (la/mUC) who are
ineligible for cisplatin-based therapy have limited first-line (1L) treatment options and …

Background Cabozantinib is approved for patients with metastatic renal cell carcinoma on
the basis of studies done in clear-cell histology. The activity of cabozantinib in patients with …

The use of targeted oral anticancer medications (OAMs) is becoming increasingly prevalent
in cancer care. Approximately 25–30% of the oncology drug pipeline involves oral agents …

Importance Dysregulated metabolism is a hallmark of renal cell carcinoma (RCC).
Glutaminase is a key enzyme that fuels tumor growth by converting glutamine to glutamate. …

Background The programmed death 1 (PD‐1) checkpoint inhibitors (CKIs) can lead to
immune‐related adverse events (irAEs). We sought to evaluate whether the development of irAEs …